TMS Health Education Announces The Advanced Transcranial Magnetic Stimulation Symposium
Published: December 23, 2015 at 8:00 am | Blackbird © 2012 All Rights Reserved.
The Advanced Transcranial Magnetic Stimulation Symposium, March 10-12, 2016, San Francisco, CA
SACRAMENTO, CA, December 23, 2015 /satPRnews.com/ — TMS Health Education, which offers accredited courses from the world’s leaders in Transcranial Magnetic Stimulation (TMS) announced that it will be hosting the first-ever Advanced TMS Symposium.
Scheduled for March 10-12, 2016 and again September 22-24, 2016, the Symposium will be accredited for CME and will feature:
Course Chair Karl I. Lanocha, MD, who has more than 25 years of experience in neuromodulation therapies for treatment-resistant depression, including both TMS and ECT. He was among the first physicians in the country to begin offering TMS when it was approved by the FDA in 2008. He has lectured widely about TMS. His research activities have focused on long-term clinical outcomes following TMS treatment for major depression.
Richard A. Bermudes, MD, Medical Director at TMS Health Solutions. He is the current president of the Clinical TMS Society, a professional association dedicated to optimizing clinical practice, awareness, and affordability of Transcranial Magnetic Stimulation therapy. He has consuLTEd with TMS industry leaders to help formulate insurance coverage policies for TMS therapy.
Mark A. Demitrack, MD, has extensive experience in the treatment of mood disorders. In his role as Chief Medical Officer of Neuronetics, Inc., his research has focused on the use of TMS for treatment-resistant major depression. In addition to his numerous publications regarding TMS in the treatment of depression, he has written extensively on the neuroendocrinology of mood disorders.
Paul E. Holtzheimer, MD, MS, the Director of the Mood Disorders Service at Dartmouth Hitchcock Medical Center, where his research is focused on the neurobiology and treatment of mood disorders, primarily treatment-resistant depression. He has been an investigator in several clinical trials of novel treatments, including TMS and deep brain stimulation, as well as numerous studies investigating the structural and functional neuroanatomy of mood disorders.
Ian A. Cook, MD, Director of the UCLA Depression Research and Clinic Program at the Semel Institute and Chief of the TMS Treatment Service in the UCLA Department of Psychiatry. His research focuses on improving existing treatments for depression and developing new treatments for depression and related disorders. As both a biomedical engineer and a physician, he is at the forefront of the rapidly expanding field of neuromodulation and recently published the first study of the newly developed synchronized TMS device.
Philip G. Janicak, MD, Director of TMS at Linden Oaks, Dr. Janicak has long been regarded as a leading expert in psychopharmacology and neuromodulation, including both TMS and ECT. He has written extensively on the long-term safety and efficacy of TMS in treatment resistant-depression, including the pivotal study leading to FDA approval of TMS.
Shawn M. McClintock PhD, MSCS, Associate Professor in Psychiatry and Behavioral Sciences and Associate Research Professor in the Department of Psychology and Neuroscience at Duke University School of Medicine. His clinical research has focused on neuropsychological evaluation and clinical outcomes assessment of patients undergoing TMS and other neuromodulation treatments for major depression and other neuropsychiatric disorders.
Mark S. George, MD, is one of the world’s leading authorities on TMS. From his pioneering work at NIH, to the publication of one of the very first studies of TMS in the treatment of depression, to the pivotal trial leading to FDA approval of TMS and the subsequent NIMH replication trial, he is rightfully regarded as one of the “fathers ” of TMS. As editor of the Journal of Brain Stimulation, he helped forge a whole new specialty of neuropsychiatric medicine. In his capacity as Director of the Brain Stimulation Laboratory at the Medical University of South Carolina, his ongoing research is now focusing on TMS in the treatment of stroke and other neurological disorders.